Minerva Neurosciences Reports $3.3 Million Net Loss in Q2 2025, Down from $8.2 Million

Minerva Neurosciences, Inc. reported a net loss of $3.3 million for the second quarter of 2025, a significant reduction from the $8.2 million loss recorded in the same period of 2024. For the first half of 2025, the company’s net loss was $7.0 million, compared to $16.8 million for the first half of 2024. The decrease in losses is attributed to a substantial reduction in research and development expenses, which fell to $1.3 million in Q2 2025 from $3.9 million in Q2 2024, primarily due to lower costs associated with drug substance validation and consultant fees. General and administrative expenses also decreased slightly to $2.1 million from $2.4 million year-over-year.

As of June 30, 2025, Minerva reported total assets of $30.4 million, down from $37.1 million at the end of 2024. The company’s cash and cash equivalents decreased to $15.2 million from $21.4 million at the end of the previous fiscal year. The accumulated deficit increased to approximately $402.4 million, reflecting ongoing operational losses. The company has not generated any revenue from product sales, as none of its product candidates have received regulatory approval.

Minerva is currently focused on the development of its lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia. Following a Complete Response Letter from the FDA in February 2024, the company is required to conduct an additional confirmatory clinical trial to address deficiencies cited in the initial New Drug Application. The FDA has confirmed that the trial can be conducted as a monotherapy, with a primary endpoint focused on the change in negative symptoms after 12 weeks of treatment.

In light of its current cash position and the need for further clinical trials, Minerva has initiated cost-reduction measures and is exploring strategic alternatives to maximize shareholder value. The company has indicated that it may need to raise additional capital to fund ongoing operations and clinical development, as its existing cash reserves are projected to be insufficient for the next twelve months. The company has also stated that it will continue to evaluate its clinical development programs and may adjust its spending based on available funding and the progress of its research initiatives.